Scancell (LON:SCLP) Sets New 12-Month Low – Should You Sell?

Shares of Scancell Holdings plc (LON:SCLP) hit a new 52-week low during mid-day trading on Thursday. The stock traded as low as GBX 90 and last traded at GBX 90.20, with a volume of 102,902 shares trading hands. The stock had previously closed at GBX 90.20.

Scancell Stock Performance

The stock has a market capitalization of £1.22 billion, a price-to-earnings ratio of -164.00 and a beta of 0.69. The company has a quick ratio of 13.01, a current ratio of 0.28 and a debt-to-equity ratio of -88.01. The stock’s 50-day simple moving average is GBX 9.62 and its 200 day simple moving average is GBX 13.86.

Scancell (LON:SCLP) last posted its quarterly earnings data on Friday, October 9th. The company reported GBX (17.30) earnings per share for the quarter. Scancell had a positive return on equity of 128.87% and a negative net margin of 116.98%. Analysts expect that Scancell Holdings plc will post -2.54 earnings per share for the current fiscal year.

About Scancell

Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.